TrialThe Lancet. Haematology2021

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.

Allison Barz Leahy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.